Radiopharmaceutical therapy (RPT) is emerging as a safe and effective targeted approach
to treating many types of cancer. In RPT, radiation is systemically or locally delivered using …

The objective of this review is to outline current major cancer targets for nanoparticle
systems and give insight into the direction of the field. The major targeting strategies that …

On the basis of the high and consistent expression of prostate-specific membrane antigen
(PSMA) in metastatic prostate cancer (PC), the goal of this study was the development …

Cisplatin is used to treat a variety of tumors, but dose limiting toxicities or intrinsic and
acquired resistance limit its application in many types of cancer including prostate. We report …

Prostate-specific membrane antigen (PSMA) is a type II integral membrane glycoprotein that
was initially characterized by the monoclonal antibody (mAb) 7E11. PSMA is highly …

Background: Stratifying prostate cancer (PCa) patients into risk groups at time of initial
diagnosis enabling a risk-adapted disease management is still a major clinical challenge …

Objectives. Prostate-specific membrane antigen (PSMA) is an integral membrane protein
highly specific for the prostate. PSMA may be clinically useful for predicting outcome in …

The use of prostate-specific membrane antigen (PSMA)-directed applications in modern
prostate cancer management has evolved rapidly over the past few years, helping to …

In recent years, several radioligands targeting prostate-specific membrane antigen (PSMA)
have been clinically introduced as a new class of theranostic radiopharmaceuticals for the …

Efforts to evaluate and discover diagnostic and therapeutic markers for prostate cancer
continue. One of these, prostate-specific membrane antigen (PSMA), a transmembrane …